Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Accumulated Expenses: 2019-2024

Historic Accumulated Expenses for Revolution Medicines (RVMD) over the last 6 years, with Dec 2024 value amounting to $96.6 million.

  • Revolution Medicines' Accumulated Expenses rose 228.81% to $256.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $256.5 million, marking a year-over-year increase of 228.81%. This contributed to the annual value of $96.6 million for FY2024, which is 29.35% up from last year.
  • As of FY2024, Revolution Medicines' Accumulated Expenses stood at $96.6 million, which was up 29.35% from $74.7 million recorded in FY2023.
  • Over the past 5 years, Revolution Medicines' Accumulated Expenses peaked at $96.6 million during FY2024, and registered a low of $18.8 million during FY2020.
  • Its 3-year average for Accumulated Expenses is $66.9 million, with a median of $74.7 million in 2023.
  • Data for Revolution Medicines' Accumulated Expenses shows a peak YoY soared of 153.66% (in 2023) over the last 5 years.
  • Yearly analysis of 5 years shows Revolution Medicines' Accumulated Expenses stood at $18.8 million in 2020, then soared by 47.58% to $27.7 million in 2021, then rose by 6.22% to $29.4 million in 2022, then soared by 153.66% to $74.7 million in 2023, then rose by 29.35% to $96.6 million in 2024.